天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook--->CAS DataBase List--->304025-09-0

304025-09-0

304025-09-0 Structure

304025-09-0 Structure
IdentificationBack Directory
[Name]

AVE-8134
[CAS]

304025-09-0
[Synonyms]

AVE-8134
AVE8134,AVE 8134
Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]propoxy]methyl]-
[Molecular Formula]

C22H23NO5
[MDL Number]

MFCD28975298
[MOL File]

304025-09-0.mol
[Molecular Weight]

381.42
Chemical PropertiesBack Directory
[Boiling point ]

554.1±60.0 °C(Predicted)
[density ]

1.209±0.06 g/cm3(Predicted)
[storage temp. ]

Store at -20°C
[solubility ]

Soluble in DMSO
[pka]

3.14±0.10(Predicted)
Hazard InformationBack Directory
[Uses]

AVE-8134 is a potent PPARα agonist, with EC50 values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.
[in vivo]

In female hApo A1 mice, AVE8134 (130 mg/kg/d, po for 12 d) dose-dependently loweres the plasma triglycerides, and increases the serum HDL-cholesterol, hApo A1 and mouse Apo E levels. In female ZDF rats, AVE8134 (3-30 mg/kg/d for 2 weeks) improves insulin-sensitivity index. In pre-diabetic male ZDF rats, AVE8134 (10 mg/kg/d for 8 weeks) produces an anti-diabetic action comparable to rosiglitazone, without the PPARγ mediated adverse effects on body weight and heart weight. In male ZDF rats, AVE8134 (20 mg/kg/d for 12 weeks) increases mRNA levels of the target genes LPL and PDK4 about 20 fold in the liver, and there is no relevant effect with rosiglitazone[1]. In post-MI rats, AVE8134 (3 mg/kg and 10 mg/kg) dose-dependently improves cardiac output, myocardial contractility and relaxation and reduces lung and left ventricular weight and fibrosis. Treatment at AVE8134 decreases plasma proBNP and arginine and increases plasma citrulline and urinary NOx/creatinine ratio. In DOCA rats, AVE8134 (3 mg/kg/d) prevents development of high blood pressure, myocardial hypertrophy and cardiac fibrosis, and ameliorates endothelial dysfunction. In old SHR, treatment with a low dose of AVE8134 (0.3 mg/kg/d) improves cardiac and vascular function and increases life expectancy without lowering blood pressure. AVE8134 reduces phenylephrine-induced hypertrophy in adult rat cardiomyocytes[2].

[IC 50]

PPARα: 100 nM (EC50, Human PPARα)
[storage]

Store at -20°C
[References]

[1] Schafer HL, et al. AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta Pharmacol Sin. 2012 Jan;33(1):82-90. DOI:10.1038/aps.2011.165
[2] Linz W, et al. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46. DOI:10.1038/aps.2009.58
304025-09-0 suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354 , +17819995354
Website: www.targetmol.com/
Company Name: TargetMol Chemicals Inc.
Tel:
Website: www.targetmol.com/
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354 , +17819995354
Website:
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Website: https://www.bocsci.com
Company Name: MedChemexpress LLC  
Tel: 021-58955995
Website: www.medchemexpress.cn
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Website: www.bio-fount.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Website: https://www.targetmol.cn/
Company Name: Biosynth Biological Technology (Suzhou) Co Ltd  
Tel: 51288865780
Website: www.biosynth.com
Tags:304025-09-0 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.